OHB's Post-Rally Reckoning: A Fortified Balance Sheet Faces Its First Margin Test

OHB shares dip 14% below 50-day average despite €1B Iris2 order; capital raise boosts equity to 43.3%, but margin guidance and dilution weigh.

The space sector has a habit of rewarding companies that land big contracts, then punishing them for the inevitable questions that follow. OHB SE is living through both phases simultaneously. The Bremen-based aerospace and defense group saw its shares surge more than 15 percent in a single week after reports of a roughly €1 billion Iris2 order for 18 MEO satellites, only to give back some of those gains as investors shifted their attention from headline-grabbing orders to the mechanics of execution.

At €245.00, the stock sits about 3.5 percent below recent levels and roughly 14 percent beneath its 50-day moving average of €285.24. The pullback reads less like a verdict on the Iris2 contract itself and more like a digestion period after a steep rally — one that was built, notably, on media reports rather than fully confirmed contract details. The exact allocation of OHB's share in the overall program has yet to be officially confirmed, a nuance that tempers some of the enthusiasm without invalidating it.

A Balance Sheet Transformed in Six Months

The more consequential development, arguably, is what happened behind the scenes in July. OHB completed a capital increase that brought in €484 million in fresh funds, lifting its equity ratio from 27.5 percent at the end of 2025 to 43.3 percent. That is a dramatic strengthening of the balance sheet, and it was a necessary one: a company that collects billion-euro orders within a single year needs both the manufacturing capacity and the financial firepower to deliver on them.

Management has indicated the proceeds will go toward production expansion, potential acquisitions, and investments in launch vehicles. For investors who have been treating OHB purely as an order-flow story, this structural rebuilding of the capital base is easy to overlook. But it carries a cost: dilution. The market has not ignored that fact, and the share price reflects it. The stock remains 64 percent below its 52-week high of €688.00, a figure that puts the year-to-date gain of 109 percent into sobering perspective.

The Operational Scorecard

The first half of 2026 delivered solid numbers. Total output rose 11 percent to €627.9 million, up from €563.5 million in the prior-year period, while adjusted EBITDA climbed 31 percent to €60.4 million from €46.2 million. The order book swelled to €3,304 million, comfortably ahead of the €3,067 million recorded a year earlier.

Management reaffirmed its full-year guidance of approximately €1,400 million in total output with an adjusted EBITDA margin between 10.5 and 11.0 percent. Those figures are respectable, but they are also precisely what the market had already priced in following the rally.

The Margin Question Takes Center Stage

The critical metric for the coming weeks is not the backlog — it is the margin. Can OHB hold its guided EBITDA range through the second half while new defense projects ramp up and absorb capacity? The stock's recent 7.2 percent one-day drop illustrates how quickly the market reacts to any whiff of uncertainty around margin sustainability, and the annualized volatility of 57 percent underscores that swings in either direction remain entirely possible.

If the margin holds within the target corridor, confidence in the 2026 guidance should firm up. If it slips, the valuation loses its central justification. The risk of a temporary effect — for instance, pull-forward effects from new defense collaborations — is real, and a guidance miss would undermine the credibility of the company's projections.

Index Momentum and the TecDAX Question

OHB's recent elevation to the SDAX has already demonstrated the power of index-driven demand. Now attention turns to the regular index review in September, when a potential promotion to the TecDAX could trigger another wave of passive inflows. The stock currently trades at €252.50, essentially at its 200-day average of €252.70 — a level that suggests expectations are already stretched after a 116 percent run since the start of the year.

A TecDAX inclusion would provide a visible catalyst for additional institutional buying. A miss, by contrast, would dent the index-momentum narrative that has supported part of the recent demand.

What Analysts Are Saying

The analyst community has largely come down on the constructive side, though with caveats. Deutsche Bank initiated coverage in early August with a buy rating and a €275 price target, pointing to roughly €35 billion in defense-related space spending earmarked for Germany over the next five years. Jefferies reaffirmed its buy recommendation on August 11 with a €280 target, explicitly citing the still-ongoing MEO negotiations as a share-price driver. Both targets sit above the current level, suggesting structural upside — provided the MEO allocation is confirmed in the reported magnitude.

The Real Test

OHB has, by most measures, done more right than wrong this year: growth, margin expansion, a fortified balance sheet, and an index promotion. The question that will define the next several months is no longer whether the company can win orders — it has demonstrated that amply — but whether it can execute them profitably with its newly strengthened capital structure.

The next concrete checkpoint comes in November with the next earnings presentation, which will reveal whether the nine-month figures still support the full-year guidance. Until then, investors are watching two things: the stability of the margin and whether the defense business can establish itself as a durable second growth pillar alongside the space segment. The September index review adds a third variable, one that could shift the demand picture regardless of operational performance.